GlaxoSmithKline to close Reliant HQ, lay off marketers

Share this article:
GlaxoSmithKline will close the Liberty Corner, NJ, headquarters of Reliant Pharmaceuticals and plans to lay off 109 workers at the site, The Star-Ledger of New Jersey reports.

GSK acquired Reliant in a $1.65 billion deal last year. Reliant had $367.5 million in sales in 2006, profiting mostly from its lead product, the blood triglyceride lowerer Lovaza. Reliant's other drugs include Dyna Circ and InnoPran XL to treat high blood pressure and Rythmol SR for abnormal heartbeats.

Among the affected positions are VP of marketing, compliance officers, payroll managers and business analysts, The Star-Ledger reported. When acquired in November 2007, Reliant had roughly 1,000 employees. Some 50 were in research and development, but the bulk were in sales and marketing.

“We have offered jobs to some of the Reliant folks,” a GSK spokesman told the newspaper. “Some of them have chosen to join us. Others have not.” The integration of the two companies is expected to wrap up by June.

In January 2007, Reliant tapped former Merck US human health president Bradley Sheares as CEO. Sheares succeded Ernest Mario, who had been CEO since 2003.

Reliant was founded in 1999 and is noted for recruiting an array of retired Big Pharma execs during its growth.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...